MedPath

Clinical Study on Stonvil Capsule to treat Kidney Stone

Phase 3
Completed
Conditions
Health Condition 1: N200- Calculus of kidney
Registration Number
CTRI/2019/04/018423
Lead Sponsor
SG Phyto Pharma Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
46
Inclusion Criteria

1.Adult subjects >=18 years of age diagnosed with Renal Calculi (both sexes inclusive)

2.Renal Calculi to be confirmed by USG. A minimum of 1 calculi; sized >=3mm with crystals.

3.Subject/LAR who is willing to give informed consent for participation, able to comprehend and understand the responsibilities during treatment period and follow up period.

4.Subjects who are willing not to participate in any other clinical trial during participation in the current trial.

Exclusion Criteria

1.Subjects with known hypersensitivity to herbal investigational product or its constituents.

2.Subjects who require or are scheduled for or have previously undergone lithotripsy.

3.Subjects with calculus condition requiring surgery; not limited to hydronephrosis, hydrocalycosis; struvite and cystic stones

4.Subjects with current or chronic infection not limited to urinary tract infection; chronic renal infection.

5.Subjects with clinically abnormal renal function parameters that are to deemed by the Investigator/ CRMC as interfering with the study objectives.

6.Subjects on medications/herbal supplements for renal calculi.

7.Subjects with immunucompromised state complications.

8.Subjects with uncontrolled diabetes, hypertension or congestive heart failure.

9.Any significant medical condition (e.g., significant psychiatric or neurological disorders, active alcohol/drug abuse, etc.), any medical condition that is unstable/poorly controlled or other factor (e.g., planned relocation) that the Investigator felt would interfere with study evaluations and study participation.

10.Subjects who have participated in any clinical study within 3 months from the date of enrolment.

11.Females who are pregnant or lactating or planning to become pregnant during the study period.

12.Subjects who mentally unable to comprehend the responsibilities and adhere to the stipulations of the protocol.

13.Subjects, who in the opinion of the Investigator/CRMC are not eligible for enrolment in the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Reduction in size of Renal Calculi: â?¥50% reduction in size of renal calculi. <br/ ><br>2.Disintegration of Renal Calculi: 100% disintegration of renal calculi <br/ ><br>3.Disintegration of Renal Calculi: â?¥50% disintegration of renal calculi <br/ ><br> <br/ ><br>Timepoint: 1. Day 1, Day 45, Day 90 <br/ ><br>2. Day 1, Day 45, Day 90 <br/ ><br>3. Day 1, Day 45, Day 90 <br/ ><br> <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
1.Pain Reduction: â?¥50% reduction in pain and symptoms associated with Renal Calculi. <br/ ><br>2.Quality of Life: Score of â?¥15 by end of study. <br/ ><br>Timepoint: 1. Day 1, Day 45, Day 90 <br/ ><br>2. Day 1, Day 45, Day 90 <br/ ><br>3. Day 1, Day 45, Day 90
© Copyright 2025. All Rights Reserved by MedPath